DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

INCY·Incyte Corporation

$.
+. (+.%)
High
$99.07
Open
$97.35
Market Cap
19.41B
52W High
$112.29
Low
$96.64
P. Close
$97.16
P/E
13.56
52W Low
$63.51
Fwd P/E
53.27
Mean Target
-
Technical Score (1D)
59
BUY
News Sentiment
57
BULLISH
Incyte is advancing its CALR antibody 989, initiating a mid-year Phase 3 trial for essential thrombocythemia (ET) following FDA discussions and breakthrough therapy designation. This trial will compare 989 against best available therapy with a 24-week endpoint, aiming for quicker results. For myelofibrosis, development remains more complex as Incyte awaits further regulatory clarity and considers composite endpoints. A subcutaneous formulation of 989 is also in development to enhance patient convenience. Investors will be watching for the commencement of the Phase 3 ET trial and any updates on the myelofibrosis development path.
Earnings Summary
Incyte Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for various medical conditions, operating within the Biotechnology industry. The company's product portfolio addresses significant unmet medical needs in areas such as myelofibrosis, lymphoma, and atopic dermatitis, with a robust pipeline targeting other serious diseases. Incyte leverages its research and development capabilities to bring novel treatments to market across the United States, Europe, Canada, and Japan. Examining Incyte's recent earnings performance reveals a mixed but generally improving trend. In Q4 2025, the company reported actual EPS of $1.80, exceeding the estimate of $1.56787, alongside revenue of $1.50684 billion, surpassing the estimate of $1.25078 billion. This followed a strong Q3 2025 where actual EPS of $2.26 significantly beat the estimate of $1.63723, with revenue at $1.36598 billion. However, the preceding quarters showed a different pattern: Q2 2025 saw actual EPS of $1.57 beat the estimate of $1.47296, while Q1 2025 reported actual EPS of $1.16 beating the estimate of $1.03274, and Q4 2024 actual EPS of $1.43 missed the estimate of $1.55448. Revenue figures are not consistently available for comparison in earlier quarters. Historically, Incyte has demonstrated a capacity for significant earnings beats, particularly in recent periods like Q3 and Q4 2025, indicating strong operational execution or favorable market reception for its products. While revenue estimates were not provided for all quarters, the actual revenue figures in the most recent periods show substantial growth. The company's ability to consistently exceed EPS expectations in the latter half of its reported earnings history suggests a positive trajectory, though the Q4 2024 miss warrants attention when analyzing longer-term trends. Recent news highlights Incyte's strategic advancements, including the initiation of a Phase 3 trial for its CALR antibody 989 in essential thrombocythemia, bolstered by a breakthrough therapy designation, and ongoing development for myelofibrosis. The company is also integrating artificial intelligence into its R&D processes through partnerships, aiming to accelerate drug discovery and enhance pipeline productivity. These developments suggest a focus on innovation and pipeline expansion. Looking ahead, investors will be watching for the commencement and progress of the Phase 3 ET trial for the CALR antibody 989 and any updates on the myelofibrosis development path. Key will be the continued impact of AI integration on R&D efficiency and pipeline execution, as well as sustained revenue acceleration and the company's ability to maintain its recent trend of exceeding EPS estimates in upcoming quarters.

EPS

EstBeatMiss
$0.85$1.25$1.65$2.05$2.44Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.82 - -
Q1'26$1.34$1.81+35.1%
Q4'25$1.57$1.80+14.8%
Q3'25$1.64$2.26+38.0%
Q2'25$1.47$1.57+6.6%
Q1'25$1.03$1.16+12.3%

Revenue

EstBeatMiss
$985M$1.1B$1.3B$1.4B$1.6BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.4B - -
Q1'26$1.2B$1.3B+5.1%
Q4'25$1.3B$1.5B+20.5%
Q3'25 - $1.4B -
Q2'25 - $1.2B -
Q1'25 - $1.1B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

INCY Stock Snapshot

INCY is currently trading at $98.04, giving Incyte Corporation a market cap of 19.41B and a P/E ratio of 13.6. Today's range spans $96.64–$99.07, with shares opening at $97.35 and moving up $0.88 (0.9%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 57/100.

Over the past year INCY has traded between $63.51 and $112.29 - the current price is +54.4% off the 52-week low and -12.7% from the high.

Systematic models flag INCY as a hold in the current environment - large-cap, Healthcare, 19.41B market cap, 59/100 (HOLD), sentiment neutral at 57/100. Price: $98.04 (in the upper portion of its 52-week range). The current P/E ratio stands at 13.6. Quant strategies at this size tier typically shift allocation toward higher-momentum names during neutral phases, but maintain a base position given the structural liquidity that prevents disorderly exits. Annual range: $63.51–$112.29.

In neutral phases, large-cap Healthcare names like INCY are often where sector rotation debates play out quietly — at 19.41B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 59/100 (HOLD) and neutral sentiment (57/100) at $98.04 (in the upper portion of its 52-week range) describe a stock that is being considered rather than avoided.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…